摘要
目的 :比较阿卡波糖和二甲双胍治疗 2型糖尿病的疗效。方法 :选择 6 0例 2型糖尿病病人 ,分为阿卡波糖组 30例 (男 ,女各 15例 )口服阿卡波糖 50～ 10 0mg ,tid。另 30例为二甲双胍组 (男性 16例 ,女性 14例 ) ,口服二甲双胍 2 50～ 50 0mg ,tid ,均用 6wk。结果 :阿卡波糖和二甲双胍均能明显降低空腹和餐后血糖 ,阿卡波糖的有效率分别为 83%和97% ,二甲双胍的有效率分别为 87%和 73%。降低餐后血糖的作用 ,阿卡波糖优于二甲双胍 (P <0 .0 1) ,而降低胆固醇的作用 ,阿卡波糖不如二甲双胍 (P <0 .0 1)。阿卡波糖不良反应为腹胀和排气增多 ,发生率为 17% ;二甲双胍为恶心和腹泻 ,发生率为 13%。结论 :阿卡波糖治疗 2型糖尿病安全有效 。
AIM: To compare the efficacy of acarbose and metformin in treating non insulin dependent diabetes mellitus (NIDDM). METHODS: Sixty patients with NIDDM were divided into two groups. Thirty patients (M15, F15; age 61 a± s 13 a) were treated with acarbose 50-100 mg po , tid×6 wk; and after 30 patients (M16, F14; age 60±12 a) with metformin 250-500 mg, po , tid×6 wk as control. RESULTS: The fasting and 2 h postprandial blood glucose were remarkably lowered after therapy by acarbose and metformin. The effective rate of acarbose were 83 % and 97 %; and the effective rate of metformin were 87 % and 73 %. Acarbose was superior to metformin (in reducing 2 h postprandial blood glucose, P <0.01). And acarbose aws worse than metformin in lowering total cholesterol (TC)( P <0.01). The rates of adverse reaction were respectively 17 % and 11 %. CONCLUSION: Acarbose is a safe and effective drug in the treatment of NIDDM.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2001年第4期280-282,共3页
Chinese Journal of New Drugs and Clinical Remedies
